Rare genetic disorders
We support innovative biotechs in Italy as they push promising research programs in rare genetic disorders towards preclinical and clinical development.
Our unique collaboration with the Telethon Foundation aims to bring Italian scientific excellence to the world stage. Our mission is to foster a thriving biotech ecosystem in Italy.
Close | Fund | AMT |
---|---|---|
2018 | Sofinnova Telethon Fund | €108 million |
Close: 2018
Fund: Sofinnova Telethon Fund
AMT: €108 million
“We come from the tech transfer world so we understand what it takes to build companies around the expertise at universities and institutions."
“There has to be more willingness to invest in the early stage. If nobody had invested in mRNA technology 10 years ago, I don't think we would have had the Covid vaccine in less than one year.”
The
Team
Companies
Related News
Sofinnova Partners announces new investment in Nephris, an innovative biotech targeting chronic kidney diseases
Lucia Faccio: Italy is a "center of excellence" for Biotech
AAVantgarde Bio appoints Ram Palanki as Chairman of its Board of Directors
Lucia Faccio comments on the increased interest from investors in the rare diseases space
Sofinnova Partners charging ahead in Italy